Advertisement

Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial

  • Robert M. AnthenelliEmail author
  • Michael Gaffney
  • Neal L. Benowitz
  • Robert West
  • Thomas McRae
  • Cristina Russ
  • David Lawrence
  • Lisa St. Aubin
  • Alok Krishen
  • A. Eden Evins
Article

Abstract

Background

Pre-treatment factors that increase smokers’ risk of experiencing neuropsychiatric adverse events (NPSAEs) when quitting smoking are unknown.

Objective

To identify baseline smoker characteristics beyond the history of mental illness that predict which participants were more likely to experience moderate to severe NPSAEs in EAGLES.

Design

A prospective correlational cohort study in the context of a multinational, multicenter, double-blind, randomized trial.

Participants

Smokers without (N = 3984; NPC)/with (N = 4050; PC) histories of, or current clinically stable, psychiatric disorders including mood (N = 2882; 71%), anxiety (N = 782; 19%), and psychotic (N = 386; 10%) disorders.

Interventions

Bupropion, 150 mg twice daily, or varenicline, 1 mg twice daily, versus active control (nicotine patch, 21 mg/day with taper) and placebo for 12 weeks with 12-week non-treatment follow-up.

Main Measures

Primary safety outcome was the incidence of a composite measure of moderate/severe NPSAEs. Associations among baseline demographic/clinical characteristics and the primary safety endpoint were analyzed post hoc via generalized linear regression.

Key Results

The incidence of moderate to severe NPSAEs was higher among smokers in the PC (238/4050; 5.9%) than in the NPC (84/3984; 2.1%). Three baseline characteristics predicted increased risk for experiencing clinically significant NPSAEs when quitting regardless of carrying a psychiatric diagnosis: current symptoms of anxiety (for every ~ 4-unit increase in HADS anxiety score, the absolute risk of occurrence of the NPSAE endpoint increased by 1% in both PC and NPC); prior history of suicidal ideation and/or behavior (PC, 4.4% increase; P = 0.001; NPC, 4.1% increase; P = 0.02), and being of White race (versus Black: PC, 2.9% ± 0.9 [SE] increase; P = 0.002; and NPC, 3.4% ± 0.8 [SE] increase; P = 0.001). Among smokers with psychiatric disorders, younger age, female sex, history of substance use disorders, and proxy measures of nicotine dependence or psychiatric illness severity also predicted greater risk. There were no significant interactions between these characteristics and treatment. Smokers with unstable psychiatric disorders or with current, active substance abuse were excluded from the study.

Conclusions

Irrespective of cessation pharmacotherapy use, smokers attempting to quit were more likely to experience moderate to severe NPSAEs if they reported current anxiety or prior suicidal ideation at baseline and were White. In smokers with a psychiatric history, female sex, younger age, and greater severity of nicotine dependence were also predictive.

Trial Registration

ClinicalTrials.gov Identifier: NCT01456936

KEY WORDS

neuropsychiatric adverse event smoking cessation medication varenicline predictors 

Notes

Contributors

Editorial support (in the form of creating tables and figures, formatting references, collating review comments, and proofing and formatting for submission) was provided by Anne Jakobsen, MSc, Engage Scientific, Horsham, UK.

Author Contribution

Sponsor employees, with input from academic authors, designed the study. The sponsors supported the conduct of the trial, monitored study sites, and collected and analyzed the data; all authors had full access to the data. The lead academic (corresponding) author (RMA) prepared the initial draft of the manuscript and had final responsibility for the decision to submit for publication.

Funders

Editorial support was funded by Pfizer. The EAGLES trial was funded by Pfizer and GlaxoSmithKline. EAGLES was a post-marketing requirement in the USA and Europe for Pfizer and GlaxoSmithKline.

Compliance with Ethical Standards

Upon request, and subject to certain criteria, conditions and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the USA and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

Conflict of Interest

RMA reports his university receiving grants from Alkermes and Pfizer and providing consulting and/or advisory board services to Arena Pharmaceuticals, Cerecor, Pfizer, and US WorldMeds. RMA’s writing of this manuscript was supported, in part, by National Institute on Alcohol Abuse and Alcoholism Grant no. U01 AA013641, and National Institute on Drug Abuse (NIDA) Grant no. UO1 DA041731, and NIDA/Veterans Affairs Cooperative Study no. 1033. NLB reports consulting and/or advisory board services to GlaxoSmithKline, Pfizer, and Achieve Life Sciences and is a paid expert witness in litigation against tobacco companies. RW reports grants from Johnson & Johnson and Pfizer and personal fees for consulting and/or advisory board services to GlaxoSmithKline, Johnson & Johnson, and Pfizer. RW’s writing of this manuscript was supported, in part, by Cancer Research United Kingdom. AEE reports grants from Forum Pharmaceuticals and Pfizer and personal fees for advisory board services from Pfizer, Reckitt Benckiser, and Alkermes. AEE’s writing of the manuscript was supported by a NIDA Career Award in Patient-Oriented Research, K24 DA030443. MG, TM, CR, DL, and LSA are employees and stockholders of Pfizer. AK is a PAREXEL employee working on behalf of GlaxoSmithKline.

Disclaimer

The opinions expressed in this article are those of the authors and do not necessarily reflect the views of their employers.

References

  1. 1.
    Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–20.CrossRefGoogle Scholar
  2. 2.
    Gourlay SG, Forbes A, Marriner T, McNeil JJ. Predictors and timing of adverse experiences during transdermal nicotine therapy. Drug Saf. 1999;20(6):545–55.CrossRefGoogle Scholar
  3. 3.
    Leventhal AM, Ramsey SE, Brown RA, LaChance HR, Kahler CW. Dimensions of depressive symptoms and smoking cessation. Nicotine Tob Res. 2008;10(3):507–17.CrossRefGoogle Scholar
  4. 4.
    Schnoll RA, Leone FT, Hitsman B. Symptoms of depression and smoking behaviors following treatment with transdermal nicotine patch. J Addict Dis. 2013;32(1):46–52.CrossRefGoogle Scholar
  5. 5.
    Morrell HE, Cohen LM, al'Absi M. Physiological and psychological symptoms and predictors in early nicotine withdrawal. Pharmacol Biochem Behav. 2008;89(3):272–8.CrossRefGoogle Scholar
  6. 6.
    Farris SG, Zvolensky MJ, Otto MW, Leyro TM. The role of distress intolerance for panic and nicotine withdrawal symptoms during a biological challenge. J Psychopharmacol. 2015;29(7):783–91.CrossRefGoogle Scholar
  7. 7.
    Ben Taleb Z, Ward KD, Asfar T, Jaber R, Auf R, Maziak W. Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting. Int J Public Health. 2016;61(6):701–8.CrossRefGoogle Scholar
  8. 8.
    World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed Dec 14 2018.
  9. 9.
    International Conference on Harmonisation. Guideline For Good Clinical Practice E6(R2). Available at: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4_2016_1109.pdf. Accessed Dec 14 2018.
  10. 10.
    First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). In: Rush Jr AJ, First MB, Blacker D, editors. Handbook of Psychiatric Measures. 2nd ed. Arlington, VA, US: American Psychiatric Publishing Inc.; 2008:40–3.Google Scholar
  11. 11.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revison. Available at: https://dsm.psychiatryonline.org/doi/abs/10.1176/appi.books.9780890420249.dsm-iv-tr. Accessed Dec 14 2018.
  12. 12.
    First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, D.C.: American Psychiatric Press, Inc.; 1997.Google Scholar
  13. 13.
    First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; November 2002.Google Scholar
  14. 14.
    Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res. 2012;14(1):75–8.CrossRefGoogle Scholar
  15. 15.
    Buss AH, Perry M. The aggression questionnaire. J Pers Soc Psychol. 1992;63(3):452–9.CrossRefGoogle Scholar
  16. 16.
    Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–77.CrossRefGoogle Scholar
  17. 17.
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefGoogle Scholar
  18. 18.
    Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013;159(6):390–400.CrossRefGoogle Scholar
  19. 19.
    Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.Google Scholar
  20. 20.
    Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;1:CD000031.Google Scholar
  21. 21.
    Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.Google Scholar
  22. 22.
    Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;5:CD006103.Google Scholar
  23. 23.
    Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend. 2008;98(3):169–78.CrossRefGoogle Scholar
  24. 24.
    Covey LS, Berlin I, Hu MC, Hakes JK. Smoking and suicidal behaviours in a sample of US adults with low mood: a retrospective analysis of longitudinal data. BMJ Open. 2012;2(3):e000876.CrossRefGoogle Scholar
  25. 25.
    Evins AE, Korhonen T, Kinnunen TH, Kaprio J. Prospective association between tobacco smoking and death by suicide: a competing risks hazard analysis in a large twin cohort with 35-year follow-up. Psychol Med. 2017;47(12):2143–54.CrossRefGoogle Scholar
  26. 26.
    Gaspersz R, Lamers F, Kent JM, Beekman AT, Smit JH, van Hemert AM, et al. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment. J Psychiatr Res. 2017;84:41–8.CrossRefGoogle Scholar
  27. 27.
    Shankman SA, Gorka SM, Katz AC, Klein DN, Markowitz JC, Arnow BA, et al. Side effects to antidepressant treatment in patients with depression and comorbid panic disorder. J Clin Psychiatry. 2017;78(4):433–40.CrossRefGoogle Scholar
  28. 28.
    Kim SK, Park SP, Kwon OY. Impact of depression and anxiety on adverse event profiles in Korean people with epilepsy. Epilepsy Behav. 2015;46:185–91.CrossRefGoogle Scholar
  29. 29.
    Perucca P, Jacoby A, Marson AG, Baker GA, Lane S, Benn EK, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology. 2011;76(3):273–9.CrossRefGoogle Scholar
  30. 30.
    Minami H, Frank BE, Bold KW, McCarthy DE. Ecological momentary analysis of the relations among stressful events, affective reactivity, and smoking among smokers with high vs. low depressive symptoms during a quit attempt. Addiction. 2017.Google Scholar
  31. 31.
    Chong RY, Uhart M, McCaul ME, Johnson E, Wand GS. Whites have a more robust hypothalamic-pituitary-adrenal axis response to a psychological stressor than blacks. Psychoneuroendocrinology. 2008;33(2):246–54.CrossRefGoogle Scholar
  32. 32.
    Shivani R, Goldsmith RJ, Anthenelli RM. Alcoholism and Psychiatric Disorders: Diagnostic Challenges. Available at: https://pubs.niaaa.nih.gov/publications/arh26-2/90-98.htm. Accessed Dec 14 2018.
  33. 33.
    LeFevre ML, Force USPST. Screening for suicide risk in adolescents, adults, and older adults in primary care: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(10):719–26.CrossRefGoogle Scholar
  34. 34.
    Siu AL, Force USPST, Bibbins-Domingo K, Grossman DC, Baumann LC, Davidson KW, et al. Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(4):380–7.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  • Robert M. Anthenelli
    • 1
    Email author
  • Michael Gaffney
    • 2
  • Neal L. Benowitz
    • 3
  • Robert West
    • 4
  • Thomas McRae
    • 2
  • Cristina Russ
    • 2
  • David Lawrence
    • 2
  • Lisa St. Aubin
    • 2
  • Alok Krishen
    • 5
  • A. Eden Evins
    • 6
  1. 1.Department of PsychiatryUniversity of California, San DiegoLa JollaUSA
  2. 2.PfizerNew YorkUSA
  3. 3.Department of MedicineUniversity of CaliforniaSan FranciscoUSA
  4. 4.University CollegeLondonUK
  5. 5.PAREXEL International on behalf of GlaxoSmithKlineResearch Triangle ParkUSA
  6. 6.Massachusetts General Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations